We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CHINA CONSIDERING NEW REGULATIONS TO CONTROL DEVICE, DIAGNOSTIC PRICES

CHINA CONSIDERING NEW REGULATIONS TO CONTROL DEVICE, DIAGNOSTIC PRICES

June 13, 2006

China recently announced it is moving forward with a healthcare initiative to control costs for devices and diagnostic tests.

Eight Chinese agencies are finalizing regulations to "unify" the cost of domestically manufactured and imported devices to eliminate price discrepancies and discourage Chinese hospitals from overcharging for services.

The proposal seeks to "reinforce control" over device prices by publishing price information, reining in factory or import supply price increases, controlling the differential between wholesale and retail prices and enforcing price monitoring.

The Chinese government is facing increasing pressure to control costs as "more and more hospitals and patients are engaging in out-of-pocket expenditures," Ames Gross, president of consulting firm Pacific Bridge Medical, told FDAnews.

AdvaMed says it is expecting the Chinese to issue a formal draft of the regulation soon but that it may not be the final version. "Our member companies have had several meetings with the people who made the regulations, and they have taken our comments into consideration and made changes," said Nancy Travis, AdvaMed's associate vice president for global strategy.

China is still developing its reimbursement policies, according to AdvaMed. The most recent general guideline issued May 19 "does not address reimbursement at all," Gross noted.

"Right now it's not clear exactly which products are covered," Travis said, noting there is a separate regulation being proposed regarding fees paid for diagnostics such as X-rays and other tests.

Chinese authorities are seeking to counter what China's State Council calls the "disguised blow out" in prices and the "practice of increasing prices in every layer" of the device procurement chain.

(http://www.fdanews.com/ddl/33_24/)

KEYWORDS FDAnews Device Daily Bulletin

Upcoming Events

  • 19Jan

    Pharmaceutical Quality Risk Management: Navigating the Intersection Between Regulatory Requirements & Risk Management

  • 21Jan

    Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Regeneron logo

    U.S. Government Orders More Supplies of Regeneron’s COVID-19 Antibody Cocktail

  • Siemens Healthineers logo

    Siemens Healthineers COVID Test Gets Additional Sampling Method Clearance

  • COVID-19  Clinical Trial

    Synairgen Initiates Dosing in Late-Stage Trial of Inhaled COVID-19 Therapy

  • Verona Pharma logo

    Verona Pharma Ends Enrollment in Inhaler-Administered COVID-19 Drug Pilot

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing